Award-winning Blinkcns Inc. and MUSC ink new deal for central nervous system disorders technology
Retrieved on:
Monday, August 8, 2022
Technology, Medical Devices, Neurology, Health Technology, Software, Biotechnology, University, Health, Data Management, Education, FDA, Reflex, ADHD, Budget, Carbon, CNS, Dentistry, Lists of diseases, Technology, Growth, Hospital, Applied Neuroscience Society of Australasia, U.S. News & World Report, Research, Life, ZI, Health care, Office of Innovation and Improvement, Patient, No, Education, Central nervous system, Innovation, Partnership, MUSC Health University Medical Center, IPad, Graduate school, Artificial intelligence, National, Duane syndrome, National Institutes of Health, Physician, Software, TBI, MUSC, Medical University of South Carolina, IPhone, Bed, Medical school, Student, Zucker, Traumatic brain injury, Pharmaceutical industry, Medicine, Nursing, Medicine, Pharmacy, Health
Central nervous system (CNS) diseases are difficult to monitor and track, as many gold-standard devices are either outdated, costly or unreliable.
Key Points:
- Central nervous system (CNS) diseases are difficult to monitor and track, as many gold-standard devices are either outdated, costly or unreliable.
- We are delighted to have established this new licensing agreement, which represents significant clinical potential for our technology.
- MUSC brought in more than $327.6 million in research funds in fiscal year 2021, leading the state overall in research funding.
- MUSC also leads the state in federal and National Institutes of Health funding, with more than $220 million.